Clinical Study
Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
Table 1
The baseline characteristics of the patients.
| | Characteristics | Overall () | Group I: peg-IFN α-2a 180 μg/week plus ribavirin () | Group II: peg-IFN α-2a 135 μg/week plus ribavirin () | Group III: peg-IFN α-2a 90 μg/week plus ribavirin () |
| | Demography and anthropometry | | | | | | Age (y), Mean (SD) | 39.8 (9.9) | 38.5 (8.8) | 38.7 (9.7) | 41.7 (10.7) | | Sex, male/female (% male) | 145/98 (59.7) | 53/34 (60.9) | 38/25 (60.3) | 54/39 (58.1) | | Mean (SD) body wt (kg) | 59.2 (12.4) | 62.5 (10.8) | 61.3 (10.4) | 57.3 (10.6) | | Genotype, n (%) | | | | | | 1 | 130 (53.5 ) | 50 (52.3) | 32 (50.8) | 48 (51.6) | | 2 | 20 (8.2%) | 4 (4.6) | 6 (9.4) | 10 (10.8) | | 3 | 60 (24.7) | 21 (24.1) | 15 (23.8) | 24 (25.8) | | 6 | 33 (13.6 ) | 12 (13.8) | 10 (15.9) | 11 (11.8) | | Diagnosis, n (%) | | | | | | Chronic hepatitis | 177 (72.8) | 66 (75.9) | 45 (71.4) | 66 (71.0) | | Cirrhosis | 66 (27.2) | 21 (24.1) | 18 (28.6) | 27 (29.0) | | ALT | | | | | | Mean (SD) ALT level, IU / L, | 97.5 (124.6) | 112.1 (164.3) | 104.2 (178.1) | 92.1 (152.7) | | No. (%) with <2 ULN | 147 (60.5) | 56 (64.4) | 39 (61.9) | 52 (55.9) | | No. (%) with ≥2 ULN | 96 (39.5) | 31 (35.6) | 24 (38.1) | 41 (44.1) | | HCV RNA level | | | | | | Median (range) HCV RNA, IU/mL × 103 | 636 (0.10–17650) | 678 (0.50–17650) | 625 (0.20–14200) | 512 (0.10–16250) | | No. (%) with <600 IU/mL × 103 | 118 (48.6) | 40 (46.0) | 28 (44.4) | 50 (53.8) | | No. (%) with ≥600 IU/mL × 103 | 125 (51.4) | 47 (54.0) | 35 (55.6) | 43 (46.2) |
|
|
Notes. SD: standard deviation, ALT: serum alanine aminotransferase levels; ULN: upper limit of normal.
|
